These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7737288)

  • 1. Simple strategy to induce antibodies of distinct specificity: application to the mapping of gp120 and inhibition of HIV-1 infectivity.
    Prieto I; Hervás-Stubbs S; García-Granero M; Berasain C; Riezu-Boj JI; Lasarte JJ; Sarobe P; Prieto J; Borrás-Cuesta F
    Eur J Immunol; 1995 Apr; 25(4):877-83. PubMed ID: 7737288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
    J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
    Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
    J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection.
    Manca F; De Berardinis P; Fenoglio D; Ombra MN; Li Pira G; Saverino D; Autiero M; Lozzi L; Bracci L; Guardiola J
    Eur J Immunol; 1996 Oct; 26(10):2461-9. PubMed ID: 8898961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a self-assembling peptide derived from the envelope proteins of HIV type 1. An approach to heterovalent immunogens.
    Tripathy SP; Kumar A; Manivel V; Panda SK; Rao KV
    J Immunol; 1992 Jun; 148(12):4012-20. PubMed ID: 1534827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG
    Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans.
    Doe B; Steimer KS; Walker CM
    Eur J Immunol; 1994 Oct; 24(10):2369-76. PubMed ID: 7523139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
    Kelker HC; Schlesinger D; Valentine FT
    J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CD4+ T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66.
    Manca F; Fenoglio D; Valle MT; Li Pira G; Kunkl A; Ferraris A; Saverino D; Lancia F; Mortara L; Lozzi L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):227-37. PubMed ID: 7540488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
    J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120.
    di Marzo Veronese F; Willis AE; Boyer-Thompson C; Appella E; Perham RN
    J Mol Biol; 1994 Oct; 243(2):167-72. PubMed ID: 7523682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F; Theze J; Zouali M
    Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.